Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain
- PMID: 10544028
- DOI: 10.1006/bbrc.1999.1599
Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain
Abstract
The phage library derived, nonphosphorylated and thioether-cyclized peptide, termed G1TE, cyclo(CH(2)CO-Glu(1)-Leu-Tyr(3)-Glu-Asn-Val-Gly-Met-Tyr-Cys(10))-amid e, represents a new structural motif that binds to the Grb2-SH2 domain in a pTyr-independent manner, with an IC(50) of 20 microM. The retention of binding affinity is very sensitive with respect to peptide ring-size alterations and Ala mutations. We demonstrated previously that the Glu(1) side chain and its closely related analogs partially compensate for the absence of the phosphate functionality on Tyr(3), and, based on molecular modeling, these acidic side-chains complex with the Arg67 and Arg86 side-chains of the protein in the binding cavity. In this study we judiciously altered and incorporated various natural and unnatural amino acids as Tyr replacements within the -YEN- motif, and we demonstrate the functional importance and structural requirement of Tyr(3) for effective binding of this novel non-phosphorylated ligand to the Grb2-SH2 domain. The phenyl side-chain moiety and a polar functional group with specific orientation in position Y(3) of the peptide are particularly required. Using SPR binding assays, a submicromolar inhibitor (IC(50) = 0.70 microM) was obtained when Glu(1) was replaced with alpha-aminoadipate and Tyr(3) was replaced with 4-carboxymethyl-Phe, providing peptide 14, G1TE(Adi(1), cmPhe(3)). Peptide 14 also inhibited Grb2/p185(erb)(B-2) protein association in cell homogenates of erbB-2-overexpressing MDA-MA-453 cancer cells at near one micromolar concentrations.
Copyright 1999 Academic Press.
Similar articles
-
Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain.Arch Biochem Biophys. 1999 Dec 15;372(2):309-14. doi: 10.1006/abbi.1999.1513. Arch Biochem Biophys. 1999. PMID: 10600169
-
Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhibitor of the Grb2-SH2 domain.J Pept Res. 2001 Jun;57(6):447-54. doi: 10.1034/j.1399-3011.2001.00833.x. J Pept Res. 2001. PMID: 11437948
-
Potentiating effect of distant sites in non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain.Biochem Biophys Res Commun. 2003 Oct 17;310(2):334-40. doi: 10.1016/j.bbrc.2003.09.022. Biochem Biophys Res Commun. 2003. PMID: 14521914
-
Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.J Med Chem. 2003 Jan 16;46(2):244-54. doi: 10.1021/jm0203635. J Med Chem. 2003. PMID: 12519063
-
Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.Biopolymers. 2003;71(2):132-40. doi: 10.1002/bip.10396. Biopolymers. 2003. PMID: 12767115 Review.
Cited by
-
Phosphotyrosine isosteres: past, present and future.Org Biomol Chem. 2020 Jan 28;18(4):583-605. doi: 10.1039/c9ob01998g. Epub 2019 Nov 28. Org Biomol Chem. 2020. PMID: 31777907 Free PMC article. Review.
-
Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.Bioorg Med Chem Lett. 2009 May 15;19(10):2693-8. doi: 10.1016/j.bmcl.2009.03.134. Epub 2009 Mar 29. Bioorg Med Chem Lett. 2009. PMID: 19362470 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous